NCT07371104

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

A Multicenter, Open-label, Randomized, Multi-dose, 2-sequence, 2-period, Crossover Bioequivalence Study to Comparison of the Pharmacokinetics and Safety of DWZ2501 and DWC202510 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: Female
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A Multicenter, Open-label, Randomized, Multi-dose, 2-sequence, 2-period, Crossover Bioequivalence Study to Comparison of the Pharmacokinetics and Safety of DWZ2501 and DWC202510 in Patients with Advanced BRCA-mutated High-grade Ovarian Cancer

Conditions

• Cancer
• Ovarian Cancer

Interventions

Type	Name	Description
DRUG	DWZ2501 (Olaparib 150mg)	Subjects receive 600 mg per day, two tablets BID (total 4 tablets), oral administration
DRUG	DWC202510 (Olaparib 150mg)	Subjects receive 600 mg per day, two tablets BID (total 4 tablets), oral administration

Timeline

• Start date: 2026-02-20
• Primary completion: 2027-03-01
• Completion: 2027-03-01
• First posted: 2026-01-27
• Last updated: 2026-03-05

Locations

1 site across 1 country: South Korea